Mitochondrial electron carrier (thiazine dye)

Methylene Blue

The ProvayBlue label gives methylene blue's half-life as approximately 24 hours in humans; the app lists 5.25 hours.1

Emerging evidence (the app's grade, not a conclusion of the sources)Get the app

Level after one dose

Methylene Blue after one dose: 50% at ~5.25 h, 25% at 10.5 h, 12.5% at 15.75 h.

Drawn from the half-life in the app's model, ~5.25 h. The model's figures

Methylene blue (methylthioninium chloride) is a water-soluble thiazine dye, and the US ProvayBlue label calls it an oxidation-reduction agent.1 That label is for ProvayBlue, an intravenous injection from American Regent, indicated for pediatric and adult patients with acquired methemoglobinemia, with an initial US approval year of 2016.1 The app lists methylene blue as an oral cognitive compound with a typical range of 5 to 20 mg/day, a route and use that the ProvayBlue label does not describe.1

The app grades the evidence for methylene blue as emerging. The studies described below are a bioavailability trial in 16 healthy people (Walter-Sack and colleagues, European Journal of Clinical Pharmacology, 2009)2, an enzyme-inhibition study (Ramsay and colleagues, British Journal of Pharmacology, 2007)3, a placebo-controlled brain-imaging trial in 26 healthy adults (Rodriguez and colleagues, Radiology, 2016)4 and a Phase III trial in Alzheimer's disease of a related, reduced form of the molecule (Wilcock and colleagues, Journal of Alzheimer's Disease, 2018).5

The label describes the action in methemoglobinemia: methylene blue is first converted to leucomethylene blue via NADPH reductase, and that form reduces the ferric iron of methemoglobin to the ferrous state of normal hemoglobin.1 The label adds that patients with G6PD deficiency "may not reduce PROVAYBLUE to its active form in vivo".1

The app describes methylene blue as an alternative mitochondrial electron carrier that cycles between oxidised and reduced forms. Rodriguez and colleagues write in the introduction of their trial that, at low concentrations in the brain, methylene blue "forms a renewable redox complex that can donate electrons to the electron transport chain, thereby promoting cytochrome c oxidase activity, oxygen consumption, and energy production".4 In their discussion they say the imaging changes "may more likely be attributed to changes in tissue oxygen consumption", reasoning from increased brain oxygen consumption measured with in vitro and in vivo animal models, a suggestion the trial did not test directly.4 The app's notes describe an inverted-U dose-response in which low doses are pro-metabolic and high doses pro-oxidant. The Wilcock group, writing about methylthioninium chloride and the reduced LMTM form, says the effect of higher doses on tau pathology "may plateau or may even become negative at brain concentrations above 1μM", an animal and in vitro inference.5

The app's notes call methylene blue a potent MAO-A inhibitor, and the label states that "literature reports suggest PROVAYBLUE is a potent reversible inhibitor of monoamine oxidase", while adding that "the mechanism is not clearly understood".1

Deeper analysis: Ramsay and colleagues' enzyme study

Ramsay, Dunford and Gillman, of the Centre for Biomolecular Sciences at the University of St Andrews, published their enzyme study in the British Journal of Pharmacology in 2007, using purified recombinant human liver MAO A and MAO B, so it is a test-tube study and not a study in people.3 The work followed case reports of severe neurological toxicity when methylene blue was infused in patients who had been taking an SSRI, and the authors write that "A search of the literature revealed no report of such toxicity from MB alone".3 Under the assay conditions used, the IC50 of methylene blue for MAO A was 164±8 nM, and tight-binding analysis gave a Ki for MAO A of 27±3 nM (mean±s.d.; n=4).3 For MAO B the authors saw no inhibition at 100 nM in the spectrophotometric assay and an IC50 of 5.5±1.7 μM in the polarographic assay.3 Their conclusion is stated for infusion: "the use of MB by infusion in combination with other 5-hydroxytryptaminergic agents could lead to the ST syndrome as a result of MAO A inhibition".3 The paper's competing-interest statement reads "The authors state no conflict of interest.", and the text names no funder.3

3

Half-life and pharmacokinetics

Values from the Milligram app's model.

Half-life
~5.25 h
Bioavailability
72%
Typical dose
5–20 mg/day
Route
Oral
Time to peak
~1.5 h

The second column of the table holds the app's own figures, shown beside what the sources report.

Table 3.1Half-life and pharmacokinetics6 rows
ParameterApp's figureReported in the sources
Half-life~5.25 hAbout 24 hours in humans on the ProvayBlue label, with no dose, route or sampling window attached to the sentence1
Bioavailability72%Absolute oral bioavailability of 72.3 +/- 23.9% for an aqueous formulation (500 mg orally against 50 mg intravenously) in 16 healthy individuals2
Time to peak~1.5 hRodriguez and colleagues cite an earlier study for a maximum whole-blood concentration 1 hour after oral dosing in healthy subjects and did not measure blood levels themselves4
Volume of distributionNot listedSteady-state volume of 255 L ± 58 after a 2 mg/kg intravenous dose; plasma protein binding about 94% in vitro1
Exposure after intravenous dosingNot listedMean Cmax 2,917 ng/mL (CV 39%) and AUC 13977 ng.hr/mL (CV 21%) after a 2 mg/kg 5-minute infusion1
EliminationNot listedAbout 40% excreted in urine unchanged; in vitro metabolism by CYP1A2, 2C19 and 2D6, with UGT-mediated conjugation the predominant pathway1

The label's half-life of approximately 24 hours and the app's 5.25 hours differ, and the label sentence does not say which route or dose the figure refers to.1 The label reports that after a single 1 mg/kg dose AUC0-96h increased by 52%, 116% and 192% in subjects with mild, moderate and severe renal impairment respectively, and that the half-life "was unchanged in patients with mild to moderate renal impairment".1

Deeper analysis: Walter-Sack bioavailability trial

Walter-Sack and colleagues, of the Department of Internal Medicine VI at Heidelberg University Hospital, reported in the European Journal of Clinical Pharmacology in 2009 a phase I study in 16 healthy individuals, a monocentre, prospective, open, randomised intra-individual crossover of single 50 mg intravenous and 500 mg oral doses of methylene blue, one week apart.2 The trial's purpose was antimalarial: the authors write that methylene blue "has recently been reevaluated for malaria treatment" and aimed to exclude treatment failures due to low bioavailability, so it was not a cognition study.2 Mean plasma AUC 0-infinity was 7,639 +/- 3,384 ng/mL*h after intravenous and 51,171 +/- 17,147 ng/mL*h after oral administration (dosage 1:10), giving an absolute bioavailability of 72.3 +/- 23.9%.2 In a parallel-group second part with chloroquine 750 mg, the authors conclude that co-administration "increases plasma, but not whole blood MB concentrations".2 The PubMed record is the only text read for this study, so the participants' age and sex, adverse events, half-life, funder and the authors' stated limitations are not reported here; the record lists the publication type "Research Support, Non-U.S. Gov't".2

4

Human studies

Queries of PubMed on 16 November 2026 for methylene blue with "memory fMRI healthy volunteers low dose" returned one randomised trial, the Rodriguez trial described below. A PubMed query for methylene blue with Alzheimer's disease and randomised trial returned 11 records, which include trials of the reduced form hydromethylthionine (LMTM). A ClinicalTrials.gov query for "methylene blue" returned 410 studies, and the 20 listed first concerned mostly photodynamic therapy, surgical marking, septic shock and other uses; none of those 20 was read.

Table 4.1Human studies4 rows
Study and yearDesignPeopleDose and lengthMain result
Walter-Sack and colleagues, Eur J Clin Pharmacol 20092Phase I, open, randomised intra-individual crossover, then a parallel-group chloroquine comparison; publication type lists non-US government research support216 healthy individuals2Single doses of 50 mg intravenous and 500 mg oral aqueous methylene blue, one week apart2Absolute bioavailability 72.3 +/- 23.9%; chloroquine co-administration increased plasma but not whole blood methylene blue concentrations; adverse events not reported in the record read2
Rodriguez and colleagues, Radiology 20164Randomised, double-blind, placebo-controlled; fMRI before and 60 minutes after dosing; grants from the National Center for Advancing Translational Sciences and the National Institute on Aging426 community volunteers aged 22–62 years, 13 per group, without neurologic, psychiatric, cardiovascular, hepatic or renal disorders4Single oral dose of 280 mg (approximately 4 mg/kg) against placebo (FD&C blue no. 2)4Higher insular fMRI response during a vigilance task and higher prefrontal, parietal and occipital response during a memory task; a 7% rise in correct retrieval responses in the methylene blue group (P = .01) with the drug × time interaction not significant (F = 2.96, P = .09); no change in cerebrovascular reactivity4
Wilcock and colleagues, J Alzheimers Dis 2018, of LMTM, a reduced salt form and not methylene blue itself5Phase III, randomised, controlled, double-blind, parallel-group; the main comparisons are non-randomised cohort analyses; sponsored by TauRx Therapeutics5800 people with mild Alzheimer's disease (MMSE 20–26), 108 sites in Canada, the United States, Australia and Europe5LMTM 100 mg or 4 mg twice a day (methylthioninium base equivalent), up to 78 weeks5Neither Phase III study showed a difference between doses in the as-randomised comparisons; the authors report differences favouring monotherapy in non-randomised cohorts; stopping for gastrointestinal and urinary events 40 of 396 (10%) on 100 mg against 9 of 399 (2%) on 4 mg5
ProvayBlue label studies (NCT03395223 and NCT03542760), US label 20251Open-label single-arm study and a multicentre observational registry; sponsor not stated in the label text131 adults with acquired methemoglobinemia, mean age 45.6 years (range 19–72)1Intravenous dose, most often 1 mg/kg (82.9% of doses), range 0.78 to 2 mg/kg126 of 28 (92.9%) with a baseline methemoglobin value had at least a 50% reduction at the first assessment after baseline; serious adverse reactions in 3.2%1

Deeper analysis: Rodriguez and colleagues, Radiology 2016

Rodriguez and colleagues, of the University of Texas Health Science Center at San Antonio and the University of Texas at Austin (Gonzalez-Lima is listed with the Austin department), reported a randomised, double-blind, placebo-controlled trial of single-dose oral methylene blue in healthy volunteers in Radiology in 2016.4 Twenty-six English-speaking volunteers were enrolled between September 2013 and December 2014 from the local community, with exclusions for neurologic, psychiatric, cardiovascular, hepatic or renal disorders, G6PD deficiency, methemoglobinemia and "ingestion of any psychiatric medication (currently or within the past 5 weeks)".4 Thirteen participants received 280 mg of oral USP-grade methylene blue (approximately 4 mg/kg, estimated for 70 kg) and 13 received a blue food colorant, and a second imaging session was acquired 60 minutes later; the dose is above the app's typical range of 5 to 20 mg/day.4 Methylene blue increased insular cortex response during the vigilance task (Z = 2.9–3.4, P = .01–.008) and prefrontal, parietal and occipital response during the memory task (Z = 2.9–4.2, P = .03–.0003).4 The behavioural result was weaker than the imaging result: correct retrieval responses rose by about 7% within the methylene blue group (P = .01) and did not change with placebo, but the percentage-correct × drug interaction "trended but was not significant (F = 2.96, P = .09)", and there was "no significant difference in the time subjects used to log a response".4 Other null results: no drug × time interaction in whole-brain mean cerebral blood flow (F = 0.85, P = .37) and no interaction in a follow-up affect questionnaire (F = 0.459, P = .505).4 On safety, the only effect the text reports is that "All subjects who received methylene blue reported voiding blue urine after leaving the imaging center" while no placebo participant reported discoloration; no other adverse-event outcome appears in the passages read.4 The authors write: "As a proof-of-concept study, the sample size was relatively small", that they "did not measure methylene blue in the blood", and that "methylene blue could have age-dependent and resting-state effects".4 The paper also reports that, within the enrolled age range of 22–62 years, only six subjects were older than 30 years, and they were evenly distributed between groups.4 Their interpretation is that "in humans, low doses of methylene blue enhance working memory processing in the brain", a conclusion from a single dose in 26 people.4 The trial was supported by grants from the National Center for Advancing Translational Sciences (UL1TR001120) and the Julio C. Palmaz, MD, Endowment for Excellence in Radiology Research, the record also lists a National Institute on Aging grant (P30 AG044271), and the disclosure statement lists no relevant relationships for any of the nine authors.4

Deeper analysis: Wilcock and colleagues, Journal of Alzheimer's Disease 2018

Wilcock and colleagues reported a Phase III trial of leuco-methylthioninium bis(hydromethanesulphonate), or LMTM, a reduced form of the methylthioninium moiety, so its results concern LMTM and cannot be read as results for oral methylene blue.5 The sponsor was TauRx Therapeutics, several authors list TauRx affiliations (Wischik CM, the corresponding author, among them), the authors' disclosures are given in the text only as an online link, and the authors state that "The funder of the study took the lead in study design, undertaking the study, data interpretation, and initial drafting of the report", while data analyses were run independently of the funder by SynteractHCR.5 The trial (NCT01689233) was an 18-month, double-blind, parallel-group trial at 108 sites in people younger than 90 with probable Alzheimer's disease of mild severity, MMSE 20–26 and CDR 0.5 or 1.0, randomised to LMTM 100 mg or 4 mg twice a day.5 The 4 mg twice a day arm was chosen "as a control to permit masking for potential urinary discoloration" and was assumed inactive.5 The as-randomised comparison was null: the authors state that "Neither of the Phase III studies showed any difference on primary or secondary outcomes between the high doses and 4 mg twice a day in the as-randomized comparisons".5 The reported benefit comes from comparisons the authors call "non-randomized cohort analyses as modified primary outcomes": "Prior to unblinding, the Statistical Analysis Plan was revised", and the revised analyses of monotherapy against add-on use were "statistically significant" for ADAS-cog, ADCS-ADL, MRI atrophy and glucose uptake.5 Monotherapy subgroups were small ("155 or 20% in total in the mITT analyses"), and the authors write that "non-obvious or unmeasured confounding factors cannot be excluded without a further randomized clinical trial comparing LMTM monotherapy with true placebo".5 Diarrhea was reported by 19.2% and 31.5% of those on 4 mg and 100 mg twice a day as add-on therapy, and by 8.4% and 29.6% of those on 4 mg and 100 mg twice a day as monotherapy.5

Deeper analysis: the ProvayBlue label studies

The label's efficacy section rests on 31 adults with acquired methemoglobinemia across an open-label single-arm study and an observational registry, and pediatric efficacy came from two retrospective case series of 14 patients, 2 of whom received ProvayBlue.1

5

Doses reported in studies and on labels

The table lists doses as the sources report them, in the populations and routes studied; none is a dose for the oral use listed in the app.

Table 5.1Doses reported in studies and on labels5 rows
SourceSetting and routeDose reportedComparator, duration and n
ProvayBlue label1Acquired methemoglobinemia in pediatric and adult patients; intravenous1 mg/kg over 5–30 minutes, with a repeat dose of up to 1 mg/kg one hour later if methemoglobin stays above 30% or symptoms persistSingle-arm labelling; 31 adults in the label studies
ProvayBlue label, pharmacokinetic study1Thorough QT and pharmacokinetic study; intravenous2 mg/kg as a 5-minute infusion; no effect on QT, PR or QRS intervalsStudy n not stated in the label text
Walter-Sack 20092Healthy individuals; intravenous and oral aqueous50 mg intravenous and 500 mg oral, single dosesCrossover, 1-week wash-out; n = 16
Rodriguez 20164Healthy volunteers; oral capsule280 mg (approximately 4 mg/kg), single dosePlacebo food colorant; imaging 60 minutes later; n = 26
Wilcock 2018, LMTM (a reduced salt form)5Mild Alzheimer's disease; oral tabletsLMTM 100 mg or 4 mg twice a day, each expressed as methylthioninium base equivalent (the 4 mg arm is 8 mg/day)Randomised between doses, up to 78 weeks; n = 800
6

Side effects reported

In the label's safety population of 31 adults with acquired methemoglobinemia, adverse reactions of at least 2% included headache, hypokalemia, diarrhea, hypomagnesemia, myoclonus, nausea and seizure-like phenomena, and one patient had a serious seizure-like phenomenon.1 The label carries a warning for "SEROTONIN SYNDROME WITH CONCOMITANT USE OF SEROTONERGIC DRUGS AND OPIOIDS" and states that "Some of the reported cases were fatal".1 The label says to "Avoid concomitant use of PROVAYBLUE with medicinal products that enhance serotonergic transmission including antidepressants like SSRIs", and its serotonin syndrome warning text refers to not taking serotonergic drugs within 72 hours after the last dose.1 The label contraindicates use in G6PD deficiency "due to the risk of hemolytic anemia" and states that treating such patients "may result in severe hemolysis and severe anemia".1 The label also lists anaphylaxis, confusion, dizziness and disturbances in vision.1 The label reports "severe intravascular hemolysis, hyperbilirubinemia and death" after a single dose of 20 mg/kg or more of a methylene blue class product.1 In animals, oral methylene blue in pregnant rabbits at 50, 100 or 150 mg/kg/day caused spontaneous abortion at all dose levels, and in a two-year rat study it "caused pancreatic islet adenomas or carcinomas (combined) in male rats"; mice showed "no drug-related neoplastic findings".1 The label also reports maternal death at 100 mg/kg and a malformation (umbilical hernia) at 100 and 150 mg/kg/day in the rabbit study, and maternal and embryofetal toxicities at all doses in pregnant rats given 50 to 350 mg/kg/day orally.1 In the LMTM Phase III trial, at least one treatment-emergent adverse event was reported by 88.2% (4 mg twice a day as add-on), 87.1% (100 mg add-on), 72.3% (4 mg monotherapy) and 86.4% (100 mg monotherapy); gastrointestinal and urinary events were the most common reasons for stopping the 100 mg twice a day dose, and the withdrawal rate over 18 months was 25% (94/296) on 4 mg twice a day and 46% (182/399) on 100 mg twice a day.5

7

Bloodwork and markers

The app lists no health markers to monitor for methylene blue. For acquired methemoglobinemia the label text says to "Monitor response to therapy with PROVAYBLUE through resolution of methemoglobinemia".1 In hemolysis the label says laboratory testing "may show Heinz bodies, elevated indirect bilirubin and low haptoglobin, but the Coombs test is negative".1 The label notes that methylene blue in the blood "may result in an underestimation of the oxygen saturation reading by pulse oximetry" and that, as a blue dye passing into urine, it "may interfere with the interpretation of any urine test which relies on a blue indicator".1 In the LMTM trial, safety checks included clinical laboratory tests "including measurement of methaemoglobin by pulse CO-oximetry".5

8

Regulatory and anti-doping status

In the United States, the ProvayBlue label gives an initial approval year of 2016 and one indication, acquired methemoglobinemia in pediatric and adult patients; the DailyMed listing for the query "provayblue" returned one label, American Regent, version 28 dated 12 June 2025.1 The text of the World Anti-Doping Agency's 2026 Prohibited List fetched on 16 November 2026 contains no entry for methylene blue or methylthioninium under those names; the list's classes (for example S5 diuretics and masking agents, and M1 manipulation of blood) were not read against the compound, so this is not a ruling on its status.6 No European Medicines Agency or Therapeutic Goods Administration document for methylene blue was read.

9

Storage and handling

Sources in this part

  1. 1American Regent, 2025

The storage text below comes from the ProvayBlue injection label and applies to that product. The label states "Store at 20°C to 25°C (68°F to 77°F); excursions permitted to 15°C to 30°C (59°F to 86°F)", "Do not refrigerate or freeze", and that the ampule or vial is kept "in the original package to protect from light".1

The label's half-life of approximately 24 hours and the app's 5.25 hours cannot be reconciled from the sources read, and the origin of the app's figure was not identified. The app's notes describe methylene blue as roughly 100 times more potent than moclobemide at low dose as a MAO-A inhibitor; the Ramsay enzyme study gives a Ki of 27±3 nM for MAO A in purified enzyme and makes no comparison with moclobemide.3 None of the sources read states the app's duration of 12 hours or its one-compartment model. The inverted-U dose-response in the app's notes is described by the sources only as animal and in vitro observations (Wilcock and colleagues) or as authors' hypothesis; no human dose-response across the app's 5 to 20 mg/day range was identified in the queries run.5,4

What is the half-life of methylene blue?

The ProvayBlue label gives a half-life of approximately 24 hours in humans, and the app lists 5.25 hours.1

What is the oral bioavailability of methylene blue?

A phase I study in 16 healthy individuals reported an absolute bioavailability of 72.3 +/- 23.9% for an aqueous oral formulation, and the app lists 72%.2 The oral dose in that study was 500 mg against 50 mg intravenous.2

Is methylene blue a MAO inhibitor?

In purified human enzyme, methylene blue inhibited MAO A with a Ki of 27±3 nM and MAO B with an IC50 of 5.5±1.7 μM.3 The ProvayBlue label states that literature reports suggest it is a potent reversible inhibitor of monoamine oxidase, and that the mechanism is not clearly understood.1

Does methylene blue interact with antidepressants?

The ProvayBlue label warns of serotonin syndrome with serotonergic drugs and opioids, and says some of the reported cases were fatal.1

Is methylene blue contraindicated in G6PD deficiency?

The ProvayBlue label lists glucose-6-phosphate dehydrogenase deficiency as a contraindication because of the risk of hemolytic anemia.1

Is methylene blue FDA approved?

The ProvayBlue injection label gives an initial US approval year of 2016 for acquired methemoglobinemia in pediatric and adult patients.1 That label does not list oral use or a cognitive indication.1

Is methylene blue banned by WADA?

The text of the WADA 2026 Prohibited List fetched on 16 November 2026 contains no entry for methylene blue or methylthioninium under those names.6 The class descriptions on the list were not checked against the compound, so this is not a ruling.6

Does methylene blue improve memory in people?

In a randomised, placebo-controlled trial of 26 healthy adults given a single 280 mg oral dose, correct retrieval responses rose about 7% within the methylene blue group (P = .01), but the percentage-correct × drug interaction was not significant (F = 2.96, P = .09).4

Does methylene blue turn urine blue?

The ProvayBlue label describes methylene blue as a blue dye that passes freely into the urine.1 In the Rodriguez trial every participant given 280 mg orally reported voiding blue urine, and no placebo participant did.4

13

References

  1. American Regent, Inc. ProvayBlue (methylene blue) injection. US prescribing information, DailyMed record version 28, 2025. DailyMed label
  2. Walter-Sack I, et al. High absolute bioavailability of methylene blue given as an aqueous oral formulation. Eur J Clin Pharmacol 2009. PMID 18810398
  3. Ramsay RR, Dunford C, Gillman PK. Methylene blue and serotonin toxicity: inhibition of monoamine oxidase A (MAO A) confirms a theoretical prediction. Br J Pharmacol 2007. PMID 17721552
  4. Rodriguez P, et al. Multimodal Randomized Functional MR Imaging of the Effects of Methylene Blue in the Human Brain. Radiology 2016. PMID 27351678
  5. Wilcock GK, et al. Potential of Low Dose Leuco-Methylthioninium Bis(Hydromethanesulphonate) (LMTM) Monotherapy for Treatment of Mild Alzheimer’s Disease: Cohort Analysis as Modified Primary Outcome in a Phase III Clinical Trial. J Alzheimers Dis 2018. PMID 29154277
  6. World Anti-Doping Agency. World Anti-Doping Code International Standard: Prohibited List 2026. WADA list